Loading
Nkarta, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 29 Mar 2024.
Nkarta, Inc.: what insiders have been doing
This page follows insider dealings at Nkarta, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector based in United States. The group dates from 2015. The last twelve months, up to 18 October 2026, brought 5 filings signed by 3 insiders.
There is no open-market purchase to report; the filings show 2 sales worth €56k by 2 insiders. At €46k, the sale published on 20 January 2026 by Hastings Paul J is the largest of the period.
Across the 5,816 companies tracked on its exchange, the median is 19 filings; at 5 filings, this issuer sits below that mark. Looking back to 2021, when coverage begins, insiders filed 4 purchases and 34 sales. For the fiscal year to 31 December 2025, the annual 10-K puts net income at -104.1 m USD.
Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
90
Thresholds
n/a
Buy Volume
€83M
4 ops. · all time
Sell Volume
€1M
34 ops. · all time
Who traded when
BuySalePaul J. Hastings3 sales
Alicia J. Hager1 sale
Alyssa Levin1 sale
David Shook1 sale
Nadir Mahmood1 sale
Ralph Brandenberger1 sale
Since the insiders bought
- -72.5%Entry US$18.77 · Close at T+365 US$5.17
- -72.0%Entry US$18.44 · Close at T+365 US$5.17
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Nkarta, Inc. Strong Buy (bullish), based on 6 analysts. Average price target: US$11.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$2.32
Analyst consensus
6 analystsStrong buy
US$9.00Target US$11.00(+375%)US$14.00
Income statement
EBITDA-US$112.8M
Net income-US$104.1M0.0% margin
Valuation
PER (forward)-1.3x
P/Book0.6x
Beta0.94
Balance sheet & cash
Market capUS$165.8M
Total debtUS$76.4M
Free Cash Flow-US$89.9M
Debt / Equity30%
Profitability & ownership
ROE-38.8%
ROA-19.6%
% insiders4.9%
% institutions83.7%
Last declaration on 20 January 2026
Declarations90 total
5,649 shares@ US$2.075.5% of flowCommon StockSEC:0001193125-26-016862:0
26,046 shares@ US$2.074.5% of flowCommon StockSEC:0001193125-26-016865:0
70,000 shares0Common StockSEC:0001193125-26-007898:0
80,000 shares0Common StockSEC:0001193125-26-007897:0
94,000 shares0Common StockSEC:0001193125-26-007896:0
1,790 shares@ US$1.790.3% of flowCommon StockSEC:0000950170-25-088501:0
5,838 shares@ US$2.20100.0% of flowCommon StockSEC:0000950170-25-006827:0
17,378 shares@ US$2.203.6% of flowCommon StockSEC:0000950170-25-006824:0
9,584 shares@ US$2.2023.1% of flowCommon StockSEC:0000950170-25-006823:0
8,638 shares@ US$2.2031.0% of flowCommon StockSEC:0000950170-25-006829:0
7,447 shares@ US$2.2011.3% of flowCommon StockSEC:0000950170-25-006826:0
59,000 shares0Common StockSEC:0000950170-25-002835:0
52,500 shares0Common StockSEC:0000950170-25-002833:0
62,000 shares0Common StockSEC:0000950170-25-002831:0
94,500 shares0Common StockSEC:0000950170-25-002827:0
52,500 shares0Common StockSEC:0000950170-25-002832:0
52,500 shares0Common StockSEC:0000950170-25-002834:0
1,352 shares@ US$5.1110.4% of flowCommon StockSEC:0000950170-24-100209:0
23,421 shares0Common StockSEC:0000950170-24-088659:0
3,396 shares@ US$8.0028.1% of flowCommon StockSEC:0000950170-24-084588:0
456 shares@ US$5.601.6% of flowCommon StockSEC:0000950170-24-075733:0
727 shares@ US$5.604.3% of flowCommon StockSEC:0000950170-24-075728:0
1,770 shares@ US$5.600.9% of flowCommon StockSEC:0000950170-24-075732:0
456 shares@ US$5.604.0% of flowCommon StockSEC:0000950170-24-075730:0
229 shares@ US$5.600.9% of flowCommon StockSEC:0000950170-24-075723:0
25 of 90 declarations
About Nkarta, Inc.
Nkarta, Inc. (Nasdaq: NKTX) is a United States-based clinical-stage biotechnology company listed on the NASDAQ market. For French, Belgian, and Swiss investors, it should be viewed as a high-risk, high-upside healthcare name with the classic characteristics of a development-stage biotech: no commercial revenues, a narrow set of clinical assets, and valuation driven primarily by trial execution and data readouts rather than near-term earnings. The company is headquartered in South San Francisco, California, a major U.S. biotech hub, and its operating footprint includes research, development, and manufacturing infrastructure in that location. Nkarta was built around engineered natural killer (“NK”) cell therapies, originally with an oncology focus and, more recently, with a strategic emphasis on autoimmune disease. ([ir.nkartatx.com](https://ir.nkartatx.com/news-releases/news-release-details/nkarta-reports-fourth-quarter-and-full-year-2025-financial/?utm_source=openai))
Nkarta’s core business is the development of off-the-shelf, allogeneic CAR-NK and related engineered NK-cell therapies. Its lead candidate, NKX019, targets CD19 and is being studied in multiple autoimmune indications, including systemic sclerosis, idiopathic inflammatory myopathy, ANCA-associated vasculitis, lupus nephritis, and primary membranous nephropathy. This positions the company at the intersection of cell therapy and immunology, where the long-term investment case depends on whether engineered NK cells can deliver deep depletion of pathogenic B cells, acceptable safety, and a durable immune “reset.” The platform model is important: if the underlying biology works, the same technology can potentially be expanded across several diseases, improving the commercial opportunity. However, as an SEC-reporting clinical-stage biotech, Nkarta remains pre-revenue and highly dependent on clinical and regulatory milestones. ([ir.nkartatx.com](https://ir.nkartatx.com/news-releases/news-release-details/nkarta-reports-fourth-quarter-and-full-year-2025-financial/?utm_source=openai))
Read moreShow less
From a competitive standpoint, Nkarta operates in a crowded and scientifically demanding field that includes other cell therapy developers, antibody-based immunology companies, and emerging autoimmune innovators. Its differentiator is its attempt to combine the scalability of an off-the-shelf cell therapy with a disease-modifying mechanism aimed at pathogenic B-cell depletion. In investor communications, the company has highlighted that its investigational therapy has shown deep B-cell depletion in treated patients and subsequent reconstitution of the B-cell compartment, consistent with the concept of immune reset. That said, competitive advantage in this segment is still unproven until later-stage data confirm efficacy, durability, and manufacturability at scale. ([ir.nkartatx.com](https://ir.nkartatx.com/news-releases/news-release-details/nkarta-reports-third-quarter-2025-financial-results-and-0?utm_source=openai))
Geographically, Nkarta’s business is concentrated in the United States, with South San Francisco serving as its headquarters and core operational base. Recent company updates have centered on the progress of NKX019, including dose escalation in 2025, enrollment across the Ntrust-1 and Ntrust-2 autoimmune trials, and conference presentations on both clinical and preclinical data. In its fourth-quarter and full-year 2025 results released in March 2026, Nkarta reported cash, cash equivalents, restricted cash, and marketable securities of $295.1 million as of December 31, 2025, and said it expects current resources to fund operations into 2029. For international investors, that cash runway is a meaningful de-risking factor, but the equity remains highly sensitive to upcoming clinical readouts and the broader sentiment toward cell therapy stocks. ([ir.nkartatx.com](https://ir.nkartatx.com/news-releases/news-release-details/nkarta-reports-fourth-quarter-and-full-year-2025-financial/?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
